p38 Mitogen-Activated Protein Kinase Inhibitors— Mechanisms and Therapeutic Potentials
- 2 May 1999
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 82 (2-3), 389-397
- https://doi.org/10.1016/s0163-7258(99)00008-x
Abstract
No abstract availableKeywords
This publication has 64 references indexed in Scilit:
- Identification of Stathmin as a Novel Substrate for p38 DeltaBiochemical and Biophysical Research Communications, 1998
- Novel Homologues of CSBP/p38 MAP Kinase: Activation, Substrate Specificity and Sensitivity to Inhibition by Pyridinyl ImidazolesBiochemical and Biophysical Research Communications, 1997
- Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammationNature, 1997
- SAP kinase‐3, a new member of the family of mammalian stress‐activated protein kinasesFEBS Letters, 1996
- SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin‐1FEBS Letters, 1995
- A MAP Kinase Targeted by Endotoxin and Hyperosmolarity in Mammalian CellsScience, 1994
- The stress-activated protein kinase subfamily of c-Jun kinasesNature, 1994
- Pyridinyl imidazoles inhibit IL-1 and TNF production at the protein levelInflammation Research, 1993
- Effect of SK&F 86002 on cytokine production by human monocytesInflammation Research, 1989
- Inhibition of monocyte IL-1 production by the anti-inflammatory compound, SK&F 86002International Journal of Immunopharmacology, 1988